Edwards Lifesciences (EW) Stock Overview
Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EW passed our risk checks.
EW Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.64 |
| 52 Week High | US$83.00 |
| 52 Week Low | US$64.89 |
| Beta | 1.05 |
| 1 Month Change | -0.74% |
| 3 Month Change | -2.42% |
| 1 Year Change | 6.22% |
| 3 Year Change | -11.99% |
| 5 Year Change | -7.18% |
| Change since IPO | 5,328.36% |
Recent News & Updates
Edwards Lifesciences: Inflection Incoming, But When?
Oct 14Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching
Sep 20
Here's What's Concerning About Edwards Lifesciences' (NYSE:EW) Returns On Capital
Sep 05Recent updates
Edwards Lifesciences: Inflection Incoming, But When?
Oct 14Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching
Sep 20Here's What's Concerning About Edwards Lifesciences' (NYSE:EW) Returns On Capital
Sep 05Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 16
Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Apr 15Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends
Apr 01Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead
Mar 23A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Mar 18At US$71.45, Is It Time To Put Edwards Lifesciences Corporation (NYSE:EW) On Your Watch List?
Feb 26Edward Lifesciences: A Closer Look At Growth And Valuation
Jan 05Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings
Dec 23Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 09At US$71.27, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?
Nov 26Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09Shareholder Returns
| EW | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.9% | 1.6% | 1.7% |
| 1Y | 6.2% | -3.1% | 14.5% |
Return vs Industry: EW exceeded the US Medical Equipment industry which returned -3.1% over the past year.
Return vs Market: EW underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| EW volatility | |
|---|---|
| EW Average Weekly Movement | 2.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EW has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EW's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 15,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| EW fundamental statistics | |
|---|---|
| Market cap | US$42.65b |
| Earnings (TTM) | US$1.41b |
| Revenue (TTM) | US$5.69b |
Is EW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EW income statement (TTM) | |
|---|---|
| Revenue | US$5.69b |
| Cost of Revenue | US$1.20b |
| Gross Profit | US$4.48b |
| Other Expenses | US$3.07b |
| Earnings | US$1.41b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.41 |
| Gross Margin | 78.87% |
| Net Profit Margin | 24.85% |
| Debt/Equity Ratio | 5.6% |
How did EW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 06:00 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Edwards Lifesciences Corporation is covered by 55 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Matthew Miksic | Barclays |
| Adam Feinstein | Barclays |